ClassID:

20385

A61K31/452 - CPC Classification

Classification description:

Medicinal preparations containing organic active ingredients; Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom; Non condensed pyridines; Hydrogenated derivatives thereof; Non condensed piperidines, e.g. piperocaine Piperidinium derivatives

Recent Application in this class:
#1
20260008751
2026-01-08

NITROXYL POLYPHENOL DERIVATIVE, METHODS FOR THE PREPARATION THEREOF AND USE THEREOF

#2
20250120960
2025-04-17

Compositions and Methods for Treatment of Inflammatory Bowel Disease

#3
20240294524
2024-09-05

HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS

#4
20240058318
2024-02-22

DEGRADING PKCB1 TO TREAT CANCER

#5
20240016788
2024-01-18

PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETIC AND POSTMENOPAUSAL OSTEOPOROSIS, CONTAINING ADIPORON

#6
20230310385
2023-10-05

TREATMENT OF ER-NEGATIVE BREAST CANCER WITH AN PDGF-CC INHIBITOR AND AN ANTI-ESTROGEN

#7
20230248734
2023-08-10

ANTIVIRAL COMPOSITION OBTAINED THROUGH DRUG REPOSITIONING

#8
20230233459
2023-07-27

ANATABINE POWDER COMPOSITIONS

#9
20230113598
2023-04-13

HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS

#10
20230097618
2023-03-30

Glycine receptor modulators and methods of use

#11
20220362238
2022-11-17

BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS

#12
20220273636
2022-09-01

Compounds for use in treating depression and migraine

#13
20220062257
2022-03-03

5-HT2A agonists for use in treatment of depression

#14
20220041552
2022-02-10

CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE

#15
20220017623
2022-01-20

TREATMENT OF CANCER USING A CEA CD3 BISPECIFIC ANTIBODY AND A WNT SIGNALING INHIBITOR

#16
20220000853
2022-01-06

FORMULATIONS, METHODS, KIT, AND DOSAGE FORMS FOR IMPROVED STABILITY OF AN ACTIVE PHARMACEUTICAL INGREDIENT

#17
20210332046
2021-10-28

NICOTINIC ACETYLCHOLINE RECEPTOR SILENT AGONISTS

#18
20210330658
2021-10-28

5-HTagonists for use in treatment of depression

#19
20210244737
2021-08-12

COMPOSITIONS FOR TREATING MELANOMA

#20
20210186932
2021-06-24

Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and anti-estrogen

#21
20210145825
2021-05-20

USE OF OPIOID ANTAGONISTS

#22
20210137908
2021-05-13

5-HTagonists for use in treatment of depression

#23
20210070752
2021-03-11

HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS

#24
20210052519
2021-02-25

Small molecule drugs and related methods for treatment of diseases related to TDP-43, alpha-synuclein, huntingtin's protein and tau protein oligomer formation

#25
20200289491
2020-09-17

Compounds for use in treating depression and migraine

#26
20200289490
2020-09-17

Charged ion channel blockers and methods for use

#27
20200247804
2020-08-06

Nicotinic acetylcholine receptor silent agonists

#28
20200215047
2020-07-09

Glycine receptor modulators and methods of use

#29
20200138964
2020-05-07

TERTIARY AMINE COMPOUND OR IMINE COMPOUND-POLYMER CONJUGATE AND PRODUCTION METHOD THEREFOR

#30
20200093822
2020-03-26

CRMP2 sumoylation inhibitors and uses thereof

#31
20190314330
2019-10-17

IRE-1α inhibitors

#32
20190247390
2019-08-15

Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions

#33
20190119268
2019-04-25

HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS

#34
20190062274
2019-02-28

Heterocyclic compound

#35
20180298002
2018-10-18

Nicotinic acetylcholine receptor silent agonists

#36
20180289700
2018-10-11

CRMP2 SUMOylation inhibitors and uses thereof

#37
20180237392
2018-08-23

Charged ion channel blockers and methods for use

#38
20180228765
2018-08-16

IRE-1α inhibitors

#39
20180170874
2018-06-21

Heterocyclic compound

#40
20180064666
2018-03-08

Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions

#41
20180008594
2018-01-11

USE OF OPIOID ANTAGONISTS

#42
20170326104
2017-11-16

IRE-1α inhibitors

#43
20170312249
2017-11-02

Modulators of 14-3-3 functionality and uses thereof

#44
20170152222
2017-06-01

Compounds and methods for inhibiting production of trimethylamine

#45
20160346260
2016-12-01

Aminoester derivatives

#46
20160331756
2016-11-17

Heterocyclic compounds useful as PDK1 inhibitors

#47
20160250163
2016-09-01

Compounds suitable for the treatment of myeloproliferative neoplasms as well as methods for the diagnosis/prognosis of myeloproliferative neoplasms

#48
20160220577
2016-08-04

Bile acid recycling inhibitors for treatment of obesity and diabetes

#49
20160136145
2016-05-19

Bitopic muscarinic agonists and antagonists and methods of synthesis and use thereof

#50
20160039756
2016-02-11

Benzyl urea derivatives for activating TGF-beta signaling

#51
20160031890
2016-02-04

Methods, compounds, and compositions for inhibition of ROS

#52
20150290182
2015-10-15

Use of aminoindane compounds in treating overactive bladder and interstitial cystitis

#53
20150250779
2015-09-10

Agent for ameliorating chronic obstructive pulmonary disease

#54
20150231127
2015-08-20

Bitopic muscarinic agonists and antagonists and methods of synthesis and use thereof

#55
20150141424
2015-05-21

IRE-1α inhibitors

#56
20150087642
2015-03-26

Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions

#57
20150038719
2015-02-05

Agent for Ameliorating Chronic Obstructive Pulmonary Disease

#58
20140309251
2014-10-16

Spirothienopyran-piperidine derivatives as ORL-1 receptor antagonists for their use in the treatment of alcohol dependence and abuse

#59
20140271734
2014-09-18

BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF BARRETT'S ESOPHAGUS AND GASTROESOPHAGEAL REFLUX DISEASE

#60
20140235864
2014-08-21

Biphenyl derivatives

#61
20140051702
2014-02-20

Use of aminoindane compounds in treating overactive bladder and interstitial cystitis

#62
20140011831
2014-01-09

Use of opioid antagonists

#63
20140005187
2014-01-02

Oxidosqualene cyclase as a protein target for anticancer therapeutics

#64
20130116247
2013-05-09

IRE-1α inhibitors

#65
20130059807
2013-03-07

Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions

#66
20120270900
2012-10-25

NOVEL METHOD OF TREATMENT

#67
20120214809
2012-08-23

Aminoindane compounds and use thereof in treating pain

#68
20120208819
2012-08-16

Heterocyclic compounds useful as PDK1 inhibitors

#69
20120157399
2012-06-21

BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF OBESITY AND DIABETES

#70
20120148684
2012-06-14

Methods useful in the treatment of bone resorption diseases

#71
20110312994
2011-12-22

Biphenyl derivatives

#72
20110294767
2011-12-01

BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS

#73
20110178068
2011-07-21

Quaternary ammonium salt prodrugs

#74
20110151025
2011-06-23

Compositions Comprising N-Halogenated or N,N-Dihalogenated Amine for Treatment and Prophylaxis of Bronchopulmonary Infections

#75
20110144082
2011-06-16

COMPOUNDS FOR THE TREATMENT OF PERIPHERAL NEUROPATHIES

#76
20110071081
2011-03-24

Methods useful in the treatment of bone resorption diseases

#77
20110065753
2011-03-17

METHODS OF TREATING POXVIRAL INFECTIONS

#78
20100286059
2010-11-11

Use of opioid antagonists

#79
20100197666
2010-08-05

(THIO) -CARBAMOYL-CYCLOHEXANE DERIVATIVES AND METHOD FOR TREATING SCHIZOPHRENIA

#80
20100130472
2010-05-27

Bile acid recycling inhibitors for treatment of obesity and diabetes

#81
20100055176
2010-03-04

Method of Treating Fibromyalgia or Associated Functional Symptoms of Fibromyalgia

#82
20090264467
2009-10-22

Agents and crystals for improving excretory potency of urinary bladder

#83
20090124627
2009-05-14

COMPOSITIONS FOR SLEEPING DISORDERS

#84
20090118192
2009-05-07

Methods useful in the treatment of bone resorption diseases

#85
20090062326
2009-03-05

M3 MUSCARINIC RECEPTOR ANTAGONISTS FOR TREATMENT OF M3 MUSCARINIC RECEPTOR-EXPRESSING TUMORS

#86
20080318847
2008-12-25

Use of Antagonist of Oxytocin and/or Vasopressin in Assisted Reproduction

#87
20080214599
2008-09-04

Use of Par-1/Par-4 Inhibitors for Treating or Preventing Vascular Diseases

#88
20080161329
2008-07-03

Pharmaceutical uses

#89
20080063704
2008-03-13

Stable gabapentin compositions

#90
20080058322
2008-03-06

Small molecule inhibitors targeted at Bcl-2

#91
20080015220
2008-01-17

Biphenyl derivatives

#92
20070276003
2007-11-29

Biphenyl derivatives

#93
20070238745
2007-10-11

PI3K-Akt Pathway Inhibitors

#94
20070208176
2007-09-06

Biphenyl derivatives

#95
20070191354
2007-08-16

Antiparasitic artemisinin derivatives (endoperoxides)

#96
20070167433
2007-07-19

3,4,5-Substituted piperidines as therapeutic compounds

#97
20070155759
2007-07-05

Pharmaceutical uses

#98
20070149543
2007-06-28

Agents For Treating Neurodegenerative Diseases

#99
20070088054
2007-04-19

Biphenyl derivatives

#100
20070078144
2007-04-05

Agents for treating neurodegenerative diseases

#101
20070060615
2007-03-15

Method of Modulating Apoptosis Through Modulation of E2F1

#102
20070037984
2007-02-15

Biphenyl derivatives

#103
20070037783
2007-02-15

Migrastatin analogs and uses thereof

#104
20070021409
2007-01-25

Antiparasitic artemisinin derivatives (endoperoxides)

#105
20060293293
2006-12-28

Salmeterol and ciclesonide combination

#106
20060287318
2006-12-21

Method for treating glaucoma III B

#107
20060287305
2006-12-21

Antiparasitic artemisinin derivatives (endoperoxides)

#108
20060281725
2006-12-14

Agents and crystals for improving excretory potency of urinary bladder

#109
20060258652
2006-11-16

Beta-blockers having antioxidant and no-donor activity

#110
20060229334
2006-10-12

Biphenyl derivatives

#111
20060223860
2006-10-05

Biphenyl derivatives

#112
20060223859
2006-10-05

Biphenyl derivatives

#113
20060223858
2006-10-05

Biphenyl derivatives

#114
20060211613
2006-09-21

Methods useful in the treatment of bone resorption diseases

#115
20060135461
2006-06-22

Reduction of hair growth

#116
20060106014
2006-05-18

Methods for treating diabetes

#117
20060063810
2006-03-23

Combination treatment for impaired motor function in parkinson's disease

#118
20060063737
2006-03-23

Liquid paroxetine compositions

#119
20060029662
2006-02-09

Immunodulatory compositions and methods of use thereof

#120
20050261167
2005-11-24

Compositions for sleeping disorders

#121
20050256165
2005-11-17

Doxepin analogs and methods of use thereof

#122
20050239838
2005-10-27

Methods of treating sleep disorders

#123
20050171160
2005-08-04

Doxepin analogs and methods of use thereof

#124
20050154016
2005-07-14

Preventives for hiv infection

#125
20050143412
2005-06-30

Methods of indirectly stimulating the vagus nerve with an electrical field

#126
20050143348
2005-06-30

Doxepin analogs and methods of use thereof

#127
20050096334
2005-05-05

Use of substance P antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia and use of NK-1 receptor antagonists for the treatment of chronic fatigue syndrome